1374295-92-7

Upstream product

• 1583-58-0 2,4-difluoro-benzoic acid 
• 106125-55-7 methyl 4-amino-2-hydroxy-5-nitrobenzoate 
• 1374298-21-1 2-[(3,5-dichloropyridin-4-yl)amino]-7,7-dimethyl-7,8-dihydro-1H-furo[3,2-e]benzimidazole-5-carboxylic acid 
• 108-91-8 cyclohexylamine 
• 179011-37-1 SRS₁₄-41 
• 153775-33-8 2,4-difluoro-5-nitro-benzoic acid 
• 22889-78-7 3,5-dichloro-4-aminopyridine 
• 1000709-58-9 3,5-Dichloro-4-isothiocyanato-pyridine 
• 1374298-19-7 methyl 4, 5-diamino-2,2-dimethyl-2,3-dihydrobenzofuran-7-carboxylate 
• 1219013-92-9 ethyl 4-(benzylamino)-2-fluoro-5-nitrobenzoate 
• 89722-54-3 methyl 4-(benzylamino)-2-methoxy-5-nitrobenzoate 
• 1374298-16-4 methyl 4-amino-2-((2-methylallyl)oxy)-5-nitrobenzoate 
• 1374298-17-5 methyl 4-amino-2-hydroxy-3-(2-methylprop-2-en-1-yl)-5-nitrobenzoate 
• 1374298-18-6 methyl 4-amino-2,2-dimethyl-5-nitro-2,3-dihydrobenzofuran-7-carboxylate 

Relevant academic research and scientific papers

Discovery of furan and dihydrofuran-fused tricyclic benzo[d]imidazole derivatives as potent and orally efficacious microsomal prostaglandin E synthase-1 (mPGES-1) inhibitors: Part-1

This letter describes the synthesis and biological evaluation of furan and dihydrofuran-fused tricyclic benzo[d]imidazole derivatives as novel mPGES-1 inhibitors, capable of inhibiting an increased PGE2 production in the disease state. Structure-activity optimization afforded many potent mPGES-1 inhibitors having 50 of 14.3 mg/kg in guinea pig.

Tricyclic Compounds As mPGES-1 Inhibitors

The present invention relates to tricyclic compounds of formula (I) or pharmaceutically acceptable salt thereof as mPGES-1 inhibitors. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful in the treatment of pain and/or inflammation from a variety of diseases or conditions, such as asthma, osteoarthritis, rheumatoid arthritis, acute or chronic pain and neurodegenerative diseases.